Evaluation of artificial intelligence based on biparameter MRI in the diagnosis of prostate cancer: a single center prospective study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068495

Enrollment

Unknown

Registered

2023-02-21

Start date

2023-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Pathological results of needle biopsy

Index test:Diagnosis of prostate cancer by magnetic resonance imaging based on artificial and AI technology

Eligibility

Sex/Gender

Male

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: The patient underwent 3.0T prostate bpMRI examination in our hospital. The patient was biopsied for the first time.

Exclusion criteria

Exclusion criteria: The patient had received prior treatment for prostate cancer; The sequence information of prostate bpMRI was incomplete. The patient had undergone prostate biopsy within 6 months prior to prostate bpMRI examination. The patient did not sign informed consent

Design outcomes

Primary

Measure	Time frame
CSPCA detection rate;	—

Secondary

Measure	Time frame
The detection rate of clinically insignificant prostate cancer;report time;Comparison results with pathological large sections as the gold standard;susceptibility;Specificity;Area under ROC curve (AUC);	—

Countries

China

Contacts

Public ContactMing Liu

Beijing Hospital

liumingbjh@126.com15573184902

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026